Literature DB >> 16050521

Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.

F G A Versteegh1, P L J M Mertens, H E de Melker, J J Roord, J F P Schellekens, P F M Teunis.   

Abstract

To investigate the possible dependence on age of the rate of decline of IgG antibodies to pertussis toxin (IgG-PT) after natural infection with Bordetella pertussis we measured IgG-PT in follow-up sera of 121 patients (age 0-94 years) obtained after 123 episodes of B. pertussis infection. For analysis we applied a dynamic model for the inactivation of B. pertussis by the immune system. There were no significant differences in rise, peak and decline of IgG-PT between different age groups, although there was a tendency for a more rapid increase, a higher peak and a faster decline with increasing age. The IgG-PT cut-off of 100 U/ml for serodiagnosis of pertussis appeared valid in all age groups. A decline of IgG-PT to < 10 U/ml was associated with increased risk of re-infection with B. pertussis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050521      PMCID: PMC2870303          DOI: 10.1017/s0950268805003833

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  29 in total

Review 1.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

2.  Sero-epidemiology as a tool to study the incidence of Salmonella infections in humans.

Authors:  J Simonsen; M A Strid; K Mølbak; K A Krogfelt; A Linneberg; P Teunis
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

3.  Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.

Authors:  Rose-Minke Schure; Lotte H Hendrikx; Lia G H de Rond; Kemal Oztürk; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

4.  Prospective evaluation of an Australian pertussis toxin IgG and IgA enzyme immunoassay.

Authors:  Meryta L May; Suhail A Doi; David King; Jenny Evans; Jennifer M Robson
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

Review 5.  Laboratory Diagnosis of Pertussis.

Authors:  Anneke van der Zee; Joop F P Schellekens; Frits R Mooi
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

6.  Seroprevalence of IgG antibodies to pertussis toxin in the Slovene population.

Authors:  Maja Socan; Katarina Prosenc; Miljana Vegnuti
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

7.  Comparison of commercially available immunoblot assays measuring IgG and IgA antibodies to Bordetella pertussis antigens.

Authors:  N Kennerknecht; M Riffelmann; J Schmetz; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-20       Impact factor: 3.267

8.  Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples.

Authors:  Sabine C de Greeff; Peter Teunis; Hester E de Melker; Frits R Mooi; Daan W Notermans; Bert Elvers; Joop F P Schellekens
Journal:  Clin Vaccine Immunol       Date:  2012-07-11

9.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

10.  Seroprevalence of pertussis in Senegal: a prospective study.

Authors:  Lobna Gaayeb; Jean Biram Sarr; Mamadou O Ndiath; Jean-Baptiste Hanon; Anne-Sophie Debrie; Modou Seck; Anne-Marie Schacht; Franck Remoué; Emmanuel Hermann; Gilles Riveau
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.